NCT01584388View on ClinicalTrials.gov

Rituximab in IgG4-RD: A Phase 1-2 Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2015

Conditions
Retroperitoneal FibrosisAutoimmune PancreatitisSialadenitisPseudotumor
Interventions
DRUG

Rituximab

Rituximab 1000 mg IV times two doses, separated by approximately 15 days.

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER